About: Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

article

Attributes	Values
rdf:type	Item
description	article (en) ലേഖനം (ml) հոդված (hy) wetenschappelijk artikel (nl) наукова стаття, опублікована в червні 2018 (uk) im Juni 2018 veröffentlichter wissenschaftlicher Artikel (de)
publication date	wds:Q56365886-902E5055-9E8C-4146-BF22-676E246F03EC
publication date	2018-06-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q56365886-B2A827CB-6191-410E-A7DC-9EBD7C9B3A8E
language of work or name	English
cites work	wds:Q56365886-076C1354-AC29-43F8-BFEF-55506839F737 wds:Q56365886-0D37B66C-B192-41A1-99D9-FAD0FDFD3AB6 wds:Q56365886-1E4AAF48-3279-4E80-9544-0FBA6764110C wds:Q56365886-4AEC2C6B-397E-4BDA-A803-2D6F175D97E1 wds:Q56365886-4BC085DC-A50D-46AF-874E-77E51E13CF2D wds:Q56365886-609951E8-9707-4035-BD50-D4D03913D5A1 wds:Q56365886-65518D47-1465-4712-A2E8-CD134E6A7906 wds:Q56365886-6664334F-0910-4C9D-9A4E-057C9F2757E2 wds:Q56365886-6CBBFBB3-170B-4606-BDEE-4949E5036A45 wds:Q56365886-7422BC8B-E581-414B-9D4D-B81464D0C67A wds:Q56365886-83233E75-876D-4EDB-9D19-F9BB96965E05 wds:Q56365886-850142C4-5224-4F2D-8BFE-61D18245F623 wds:Q56365886-881E53DB-B934-4A93-B513-E75B1F38556E wds:Q56365886-8A9CB07B-B2F3-4DB7-8883-46142C7BFA70 wds:Q56365886-8DE53B97-919F-4546-9D5E-D928C666208D wds:Q56365886-AF4E5A96-B4A2-40E7-AEAA-9611198726A9 wds:Q56365886-BD15BD79-37E3-4C8B-8A5C-68CF019674F6 wds:Q56365886-DCA1AD49-95D6-4A94-A571-48B13679965D wds:Q56365886-DE67CA99-84D7-477D-B921-CD50C7030F2C wds:Q56365886-E720B44C-76E0-4AC8-ADD4-50906E731B93 wds:Q56365886-EE04C8DB-976F-4985-918B-9E2D14B6C539 wds:Q56365886-FA689ABF-DDC9-4DAB-B58B-1018D4CDD362
cites work	Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study Increased survival with enzalutamide in prostate cancer after chemotherapy Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001-2007 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial Cancer Statistics, 2017. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial Trends in prostate cancer in the United States Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15). Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature Disease and Treatment Characteristics of Men Diagnosed With Metastatic Hormone-Sensitive Prostate Cancer in Real Life: Analysis From a Commercial Claims Database
author name string	wds:Q56365886-0633C6F9-ED89-45BB-A678-B961F312AEF7 wds:Q56365886-170A2FA5-7E17-4929-8CFC-8701153F6E23 wds:Q56365886-1F350ADA-BBBF-457A-A80A-E49650EDFC52 wds:Q56365886-54B3889F-91C7-43F5-AA4E-DF5721125C13 wds:Q56365886-664AE383-591E-406A-BD8F-E99D0571AFA1 wds:Q56365886-79274744-2C6A-43A5-A16A-37450B03B4E7 wds:Q56365886-9A4DED1B-8E3C-4572-8F3D-B792F4BC1D2A wds:Q56365886-9FD9B1FC-0361-4999-8659-976DB1768AC1 wds:Q56365886-A83BE60A-2088-4E70-9DF2-424D703BE94B wds:Q56365886-B25C32BE-B94E-411E-83CF-B5616FC6B003 wds:Q56365886-B637F84D-FB25-4F0B-930C-E7AA82EC0BBB wds:Q56365886-C1A718E0-F118-4BAA-AE8C-297A286867E7 wds:Q56365886-C53658A8-B780-4796-94FF-3DDA608D95C1 wds:Q56365886-CB77DBE2-533C-4CBA-B31E-9A77A2B83C43 wds:Q56365886-D47B7C79-D220-42BE-B188-20AE1D48FE63 wds:Q56365886-D842B533-5852-41AD-8D32-F601133E7B87 wds:Q56365886-F2895812-459A-4A3A-B0DE-10AACBD76006
author name string	Jorge A Garcia Michael A Carducci Robert Dreicer Stephane Oudard Manish Kohli Christopher Sweeney Nicholas J Vogelzang Michel Soulie Joel Picus Glenn Liu Yu-Hui Chen Robert DiPaola Muriel Habibian Gwenaelle Gravis David M Jarrard Maha H M Hussain Mario J Eisenberger
rdfs:label	Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies (en) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies (nl)
skos:prefLabel	Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies (en) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies (nl)
name	Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies (en) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies (nl)
author	wds:Q56365886-69FF7B1A-ACDF-41C0-A123-2746AADBED07 wds:Q56365886-96FA5E74-8EC5-43E7-BDF5-F04822AB7F6B wds:Q56365886-EB459B62-5020-4DB1-B0A9-83191AFE32EA
author	Karim Fizazi Florence Joly

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software